1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3–targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer
    Review

    Sands, J. M.; Champiat, S.; Hummel, H. D.; Paulson, K. G.; Borghaei, H.; Alvarez, J. B.; Carbone, D. P.; Carlisle, J. W.; Choudhury, N. J.; Clarke, J. M.; more...
    Cancer (2025)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
    Journal Article

    André, T.; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; Alcaide-Garcia, J.; Gibbs, P.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: A multicentre, single-arm, phase 2 trial
    Journal Article

    Heinzerling, J. H.; Mileham, K. F.; Robinson, M. M.; Symanowski, J. T.; Induru, R. R.; Brouse, G. M.; Corso, C. D.; Prabhu, R. S.; Haggstrom, D. E.; Moeller, B. J.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Journal Article

    Lau, G.; Abou-Alfa, G. K.; Cheng, A. L.; Sukeepaisarnjaroen, W.; Van Dao, T.; Kang, Y. K.; Thungappa, S. C.; Kudo, M.; Sangro, B.; Kelley, R. K.; more...
    Journal of Hepatology (2025)

    Fulltext@MSK | Save
  • Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
    Journal Article

    Gyurkocza, B.; Nath, R.; Seropian, S.; Choe, H.; Litzow, M. R.; Abboud, C.; Koshy, N.; Stiff, P.; Tomlinson, B.; Abhyankar, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: Part b of the randomized, placebo-controlled, phase III CheckMate 914 Trial
    Journal Article

    Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H. J.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthélémy, P.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma
    Review

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Pacritinib response is associated with overall survival in myelofibrosis: PERSIST-2 landmark analysis of survival
    Journal Article

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
    European Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Addition of elotuzumab to backbone treatment regimens for multiple myeloma: An updated meta-analysis of randomized clinical trials
    Journal Article

    Costa, B. A.; Costa, T. A.; Chagas, G. C. L.; Mouhieddine, T. H.; Richter, J.; Usmani, S. Z.; Mailankody, S.; Rajeeve, S.; Hashmi, H.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial
    Journal Article

    Iyengar, N. M.; Scott, J. M.; Lee, J.; Lavery, J. A.; Foug, K. L.; Lee, C. P.; Michalski, M. G.; Chun, S. S.; Harrison, J.; Moskowitz, C. S.; more...
    Cancer (2025)

    Fulltext@MSK | Save